Delamanid for Multidrug-Resistant Pulmonary Tuberculosis

2012732 citationsJournal Articlebronze Open Access

Authors

Maria Tarcela Gler · Tropical Disease Foundation

Vija Skripconoka · State Education Development Agency

Epifanio Sànchez-Garavito · Universidad Privada Sergio Bernales

Heping Xiao · Shanghai Pulmonary Hospital

José Luis Cabrera · Hospital Nacional Cayetano Heredia

Dante E. Vargas-Vasquez · Hospital San Hipólito

Mengqiu Gao

Abstract

Delamanid was associated with an increase in sputum-culture conversion at 2 months among patients with multidrug-resistant tuberculosis. This finding suggests that delamanid could enhance treatment options for multidrug-resistant tuberculosis. (Funded by Otsuka Pharmaceutical Development and Commercialization; ClinicalTrials.gov number, NCT00685360.).

Topics & Keywords

Tuberculosis Research and Epidemiology Mycobacterium research and diagnosis Pneumocystis jirovecii pneumonia detection and treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 366, Issue 23, pp. 2151-2160

DOI: 10.1056/nejmoa1112433

Field-Weighted Citation Impact: 35.78